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abstract
During the last decades, the evolution of treatment − including radiotherapy,
chemotherapy and targeted agents − has improved the cure and survival of patients
with gastrointestinal (GI) cancer. Within the past 50 years of the EORTC’s existence,
signiﬁcant progress has been made in the ﬁght against cancer. During this time
several cancer clinical trials were completed, and through these we are able to
identify the most notable advances in GI cancer research done by the EORTC
Gastrointestinal Tract Cancer Group (GI Group). Several EORTC clinical trials results
have changed practice (e.g. standard of care of liver metastases of colorectal cancer
has been changed by the EPOC trial) or have helped to support new treatment
strategies in either early- or advanced-stage GI cancers. In addition to its clinical
activities the group has started an extensive program of translational research. This
changed strategy towards a translational, multidisciplinary program regarded as the
basis for future developments. This review of the major achievements of the GI Group
shows that it has played an important role in the scientiﬁc development of the
understanding and treatment of GI cancer over the last 50 years.
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1. Introduction
During the last decades, the evolution of treatment −
including radiotherapy, chemotherapy and targeted
agents − has improved cure and survival of patients
with gastrointestinal (GI) cancer.Within the past 50 years
of the EORTC’s existence, signiﬁcant progress has been
made in the ﬁght against cancer. During this time several
cancer clinical trials were completed, and through these
we are able to identify the most notable advances in
GI research done by the GI Group.
Since the beginning of the new millennium, the
GI Group has been well aware that translational
research (TR) and biobanking would be a major issue
in the EORTC strategy for the future. Translational
research was implemented into the agenda of the
GI Group as early as 2002 by integrating pathologists
into the group and into the translational research
discussions of studies. As a result, initiatives such as
biobanking, screening platforms for molecular pathway
driven trials, and biomarker driven clinical trials have
been launched with the objective of improving cancer
therapy outcomes.
Optimizing treatment for each individual patient by
tailoring it to the patient’s molecular proﬁle or by using
imaging for early prediction of response/non-response
to speciﬁc drugs are ways towards a more efﬁcient
management of GI cancer and are therefore priorities for
the GI Group. Designing clinical trials will become more
complex in the future. It will require multidisciplinary
team efforts. Methodologists will have to face the
challenge of having to screen a large number of patients
in order to enroll only some with the desirable features in
a given clinical trial. New innovative designs and imaging
techniques will have to be pushed forward for screening
drugs in more complex phase II trials in order to identify
the more promising drug for the targeted population
at an early stage. The capability for rapid accrual of
a sufﬁcient number of patients having some desirable
molecular features for the testing of a targeted therapy
will be key to obtain convincing results.
In this report we summarize only studies that
signiﬁcantly altered the way GI cancer is understood or
that had a direct effect on patient care.
2. Major Gastrointestinal Tract Cancer Group
achievements in the last 50 years
2.1. Colorectal cancer
2.1.1. Early-stage and locally advanced disease
The GI Group was one of the leading groups in oncology
to test the hypothesis of neoadjuvant treatment for
rectal cancer in the 1980’s. At that time the value of
preoperative radiotherapy was unknown, and surgery
techniques such as total mesorectal excision (TME) were
not yet established. Thanks to joint collaborations with
other groups, the EORTC participated actively in the
evolution of the treatment of rectal cancer.
Preoperative radiotherapy decreases the risk of developing
local recurrence after surgical resection of rectal adenocarci-
noma. In the 1980s, a phase III EORTC study included 466
patients to assess the effectiveness of radiation therapy
administered before radical surgery for rectal cancer. 1
This trial failed to demonstrate a signiﬁcant beneﬁt
of radiation therapy in terms of overall survival (OS),
but importantly demonstrated a decrease in the risk of
developing local recurrence after surgical resection of
rectal adenocarcinoma. The GI Group joined the Dutch
Colorectal Cancer Group (DCRCG) trial which showed
that short-term preoperative radiotherapy reduces the
risk of local recurrence in patients with rectal cancer who
undergo a standardized total mesorectal excision. 2
In parallel, other EORTC groups published key studies
in this area, such as EORTC trial 22921 which showed
that in patients with stage T3 or T4 resectable
rectal cancer treated with preoperative radiotherapy,
adding ﬂuorouracil-based chemotherapy preoperatively
or postoperatively has no signiﬁcant effect on survival.
Regardless of timing, chemotherapy provides a signif-
icant beneﬁt with respect to local control. 3 Moreover,
the GI Group is currently recruiting patients in the
PETACC6 trial (EORTC 40054) which is evaluating the
addition of perioperative oxaliplatin to preoperative
chemoradiotherapy and postoperative chemotherapy
with capecitabine in locally advanced rectal cancer.
Investigating the beneﬁt of adjuvant chemotherapy in colon
cancer: the Pan-European Trials in Adjuvant Colon Cancer
(PETACC) initiative. The GI Group launched the Pan-
European Trials in Adjuvant Colon Cancer (PETACC)
effort which had the objective of investigating the
treatment of CRC in early-stage disease. The ﬁrst study
(PETACC1) started in 1998 and evaluated raltitrexed
to the standard leucovorin/bolus 5-FU. 4 Following it,
other PETACC trials were initiated that tested different
drugs and regimens such as high-dose infusional 5-FU,
irinotecan, celecoxib and cetuximab. 5,6 One of the most
important trials, despite having negative results, was
PETACC3 (EORTC 40993) trial that has shown that
the addition of irinotecan to adjuvant 5FU/LV regimen
increases toxicity and has no signiﬁcant beneﬁt in
the adjuvant treatment of stage III colon cancer, even
if combined with a modern 5-FU schedule. The trial
was initiated when oxaliplatin and irinotecan were
regarded as equally effective ﬁrst-line combinations
for advanced CRC when combined with 5-FU/FA. The
success achieved with such regimens in the treatment
of advanced disease prompted their examination in the
adjuvant setting. The PETACC-3 study included 2094
stage III patients from 368 sites in 31 countries. 5 After
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a median follow-up of 66.3 months, the 5-year disease-
free survival (DFS) rate was 56.7% with irinotecan/LV5FU2
and 54.3% with LV5FU2 alone (P=0.106). The data
from PETACC-3 are consistent with those from other
studies such ACCORD-02 and CALGB-C89803 which
failed to demonstrate an efﬁcacy beneﬁt of adding
irinotecan to bolus FU/LV in adjuvant treatment of
colon cancer. A major advantage of these adjuvant trials
is the collection of biomaterial that allowed further
translational research as outlined below.
2.1.2. Curative treatment of liver metastases
The GI Group has performed important research in
advanced colorectal cancer where cure can be achieved
by treatment of liver metastases. The EORTC 40983
(EPOC) trial was a landmark in this ﬁeld and established
perioperative chemotherapy as a standard of care for
patients with stage IV CRC with potentially resectable
liver metastases.
Perioperative chemotherapy for resectable metastatic liver
metastasis of colorectal cancer improves DFS. Liver metas-
tases occur in approximately 40% of patients with CRC
and are the principal cause of death in these patients.
In spite of progress observed in chemotherapy for
advanced colorectal cancer, survival rates remain very
low in patients with unresectable liver metastasis of
CRC (LMCRC). Surgical resection is presently the only
treatment offering potential cure when liver metastases
are resectable; long-term survival following resection is
in the order of 25−30%. Despite the beneﬁt of resection
of liver metastasis, relapse is common and occurs
in up to 75% of patients. In order to improve the
outcome of these patients, the phase III EPOC trial
(EORTC 40983) was designed to evaluate the efﬁcacy of
perioperative chemotherapy with oxaliplatin combined
with 5-ﬂuorouracil/leucovorin (FOLFOX4) regimen as part
of treatment for resectable liver metastasis of CRC. 7 The
study demonstrated that perioperative chemotherapy
with FOLFOX4 is compatible with major liver surgery
and reduces the risk of events of progression-free
survival (PFS) in eligible and resected patients. The three-
year PFS rate was improved by 7.3% (35.4% vs. 28.1%;
HR 0.79; P=0.058) in all randomized patients, by 8.1%
(P=0.041) in eligible patients, and by 9.2% (P=0.025) in
resected patients. It is to date the largest phase III
clinical trial organized in this indication and has set the
new international standard of care in patients who are
candidates for resection of liver metastasis from CRC.
In the same way, a less invasive approach such
as radiofrequency ablation (RFA) has been applied in
metastatic CRC to reduce the survival gap between
resectable and unresectable disease. This strategy was
tested in a recent EORTC prospective study described
below.
RFA together with chemotherapy improves PFS in patients
with unresectable liver metastases of CRC. The CLOCC trial
(40004) was the ﬁrst study that prospectively investigated
the efﬁcacy of RFA in combination with CT in patients
with unresectable CRC liver metastases (LM). This
phase II study randomized patients between CT alone
(FOLFOX for six months) or RFA plus CT. Of the 119
patients included, 60% had 4 LM, 85% received CT in
the RFA+CT arm and all in the CT arm. Patients in
the RFA+CT arm had a 30-months OS rate of 61.7%
(95%CI: 48.2–73.9). RFA plus systemic treatment resulted
in a signiﬁcant beneﬁt on PFS; at a median follow
up of 4.4 years the median PFS was 16.8 months
and 9.9 months (HR=0.63, 95% CI: 0.42–0.95; P=0.025)
for RFA+CT and CT alone, respectively. This study
does not allow a formal survival comparison between
treatment arms but contributes in showing the efﬁcacy
of local tumor ablation by RFA for patients with
unresectable colorectal liver metastases. 8
2.1.3. Palliative treatment of metastatic disease
The GI Group has also developed clinical trials for
patients in advanced-stage disease considered to be
incurable (e.g. unresectable liver metastases) with several
chemotherapy combinations. EORTC trials 40983 and
40986 contributed to one of the current standard
chemotherapy backbones − infusional 5-FU/leucovorin in
combination with irinotecan − in ﬁrst-line treatment of
metastatic colorectal cancer.
Irinotecan added to 5 ﬂuorouracil/leucovorin regimen
improves PFS in metastatic CRC. EORTC trial 40986 was
a phase III study that included 430 patients with
the objective to demonstrate that adding irinotecan to
a standard weekly schedule of high-dose, infusional
ﬂuorouracil (FU) and leucovorin (folinic acid) can prolong
PFS in metastatic colorectal cancer. 9 The median PFS
in the experimental group (irinotecan) was 8.5 months
compared to 6.4 months in the standard arm (P0.0001),
and the objective response rate was high in the
experimental arm, 62.2% versus 34.4% (P0.0001). No
signiﬁcant difference in survival was noted. The results
of this study, together with the cooperative group trial
V303, conﬁrmed that irinotecan in combination with
high-dose infusional 5FU/LV is a reference ﬁrst-line
treatment for metastatic CRC. 10
2.2. Esophagogastric cancer
Carcinomas of the stomach and gastroesophageal junc-
tion are among the top ﬁve leading cancer types world-
wide. In recent years, multimodal strategies combining
neoadjuvant and/or adjuvant protocols and palliative
chemotherapeutic protocols combined with new targeted
agents have clearly improved the treatment options
and prognosis in advanced esophagogastric cancer. Over
the past two decades, the GI Group has continuously
contributed to this scientiﬁc process and inspired the
further development of new therapeutic strategies for
this still often fatal disease.
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2.2.1. Early-stage and locally advanced disease
The concept of neoadjuvant treatment is based on sev-
eral theoretical advantages, such as treatment of tumor
and surround tissue intact vascularization, monitoring
response, less radical surgery, and better tolerability
among others. Additionally, because of the food intake
difﬁculties linked to gastrectomy, chemotherapy is less
likely to be well tolerated after surgery in this disease.
On the other hand, inaccurate clinical staging, peritoneal
carcinomatosis, bleeding or obstructive complications,
and progressive disease during treatment with conse-
quent inoperability are all challenges in applying the
concept of neoadjuvant treatment in esophagogastric
cancer. 11 The EORTC ran an important study to evaluate
the role of neoadjuvant chemotherapy in the treatment
of gastric cancer.
Neoadjuvant chemotherapy for locally advanced cancer of the
stomach and cardia signiﬁcantly increased R0 resection rate. In
spite of radical surgical R0 resections being the basis of
cure of gastric cancer, surgery alone provides long-term
survival in only ~30% of patients with locally advanced
UICC stages inWestern countries because of a high risk of
recurrence and metachronous metastases. Patients with
locally advanced gastric cancer beneﬁt from combined
pre- and postoperative chemotherapy, although fewer
than 50% could receive postoperative chemotherapy.
The EORTC 40954 trial examined the value of purely
preoperative chemotherapy in a phase III trial with strict
preoperative staging and surgical resection guidelines.
Patients with locally advanced adenocarcinoma of the
stomach or esophagogastric junction (AEG II and III)
were randomly assigned to preoperative chemotherapy
with cisplatin, leucovorin and ﬂuorouracil (PLF) for
12 weeks followed by surgery or to surgery alone. 12
This trial showed a signiﬁcantly increased R0 resec-
tion rate (81.9% after neoadjuvant chemotherapy as
compared with 66.7% with surgery alone, P=0.036)
but failed to demonstrate a survival beneﬁt. Although
this study could not demonstrate a signiﬁcant survival
advantage for neoadjuvant chemotherapy over surgery
alone, the results indicate that sophisticated staging,
including endosonography, CT and laparoscopy followed
by quality-controlled surgery with D2 lymphadenectomy
leads to a much better outcome than seen in other
contemporary randomized European trials. 13 In contrast
to the previous studies, EORTC trial 40954 leaves us
with some doubt as to whether one preoperative
chemotherapy concept ﬁts all gastric tumors. Our
perception is that we still have to know more about
tumor biology and learn how to select the right patients
for the appropriate treatment.
Preoperative chemoradiotherapy improves DFS and local
recurrence in patients with esophageal cancer. The GI Group
participated in a randomized trial comparing preop-
erative chemoradiotherapy followed by surgery versus
surgery alone in patients with squamous-cell esophageal
cancer. Preoperative chemoradiotherapy did not improve
OS, but it did prolong DFS and survival free of
local disease. 14
2.2.2. Metastatic disease
For a long period of time, gastric carcinoma was
considered to be a poorly chemoresponsive tumor. The
so-called ‘ﬁrst-generation’ drug combinations, designed
before the introduction of cisplatin for the treatment of
this disease, gave disappointing results. 15 The EORTC has
participated in the evolution of chemotherapy regimens
from FAM in the 1980s to FAMTX in the 1990s and then
to cisplatin-based regimens in this decade.
Establishing the best chemotherapy regimens for metastatic
gastric cancer: from FAMTX to 5-FU/FA/cisplatin regimen.
The GI Group has developed the FAMTX regimen and
has shown that FAMTX is superior to the FAM regimen
that was considered the standard regimen in the
1980’s and early 1990’s. 16 Consequently, in the mid-
1990’s FAMTX was considered the standard regimen
for patients with advanced gastric cancer. EORTC trial
40902 later showed that FAMTX is not better than
5-FU/cisplatin in advanced gastric cancer. 17 Today, 5-FU-
and cisplatin-based regimens are considered as standard
regimens in advanced gastric cancer. The most recent
GI Group trial has contributed to this knowledge; we have
shown that 5-FU/FA/cisplatin is better than 5-FU/FA and
infusional 5-FU. 18
In the last few years, the discovery of tumor-speciﬁc
biomarkers has provided the basis for the development
of targeted therapies in esophagogastric cancer.
Individualization is on the way to becoming key in the
treatment of advanced esophagogastric cancer. Very recently
it was shown that a subgroup of 20% of gastric cancers
exhibit overexpression of Her2neu. This subgroup of
patients has a beneﬁt from adding trastuzumab, an
anti-Her2 directed monoclonal antibody to cisplatin and
ﬂuorouracil chemotherapy. 19 Lapatinib is a small molec-
ular tyrosine kinase inhibitor that targets both EGFR1 and
HER2, is active in HER2+ gastric cell lines, and has shown
clinical activity in uncontrolled phase II gastric cancer
trials. In the recently started EORTC 40071 study, about
350 patients with advanced esophagogastric adenocar-
cinoma will be screened centrally for HER2/EGFR1 by
ﬂuorescence-in-situ hybridisation (FISH) and immuno-
histochemistry (IHC). Patients will be enrolled into one of
three strata: (1) HER2FISH+ and IHC2/3+, (2) HER2FISH−
and IHC2/3+, or (3) HER2 IHC 0/+ and EGFR1FISH+ or
IHC2/3+. This is the ﬁrst trial to analyze prospectively
and separately the role of HER2 and EGFR1 by FISH and
IHC for lapatinib combined with chemotherapy in gastric
cancer. Hence one of the main questions of this trial is
whether the tumor EGFR over-expression will translate
into lapatinib beneﬁt in clinical practice.
Thus, coming from an active history with successful
clinical studies, the group will further continuously
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contribute to the development of new therapeutic
strategies and translational research for the beneﬁt of
patients with esophagogastric cancer.
2.3. Pancreatic cancer
World-wide the incidence of pancreatic ductal ade-
nocarcinoma (PDAC) continues to increase and ranks
as the fourth commonest cause of cancer death. 20 In
patients with resectable disease, adjuvant chemotherapy
more than doubles the 5-year survival rate, from about
10% with surgery alone to around 25% with post-
operative chemotherapy. 21−23 On the other hand, level I
evidence for adjuvant chemoradiotherapy is lacking and
its role is still controversial, especially in Europe. One of
the biggest studies ever in this setting was done by the
GI Group.
Adjuvant chemoradiation (with 5-ﬂuouracil) does not
improve OS in patients with resected pancreatic cancer.
A phase III trial (EORTC 40891) was performed to test
adjuvant radiotherapy and 5-FU after curative resection
of cancer of the pancreas or the peri-ampullary region.
No survival beneﬁt of adjuvant chemoradiation over
observation was noted (19 vs. 24.5 months, P=0.208),
also no reduction of locoregional recurrence rates was
apparent in the groups. 24 Later on, a long-term follow-
up of this trial conﬁrmed no beneﬁt of adjuvant
chemoradiation over observation and enforced the bad
prognosis of this disease showing a 10-year OS of 18% in
the study population. 25 Although this trial was basically
negative, it served as a background for the preparation of
a future trial.
Improving strategies in pancreatic cancer research. Al-
though adjuvant chemotherapy is now considered as
standard after resection, the GI and RO groups have
completed a randomized phase II trial showing the
feasibility of combining adjuvant gemcitabine and
chemoradiation. 26 This concept was further incorporated
in the design of a large intergroup US-RTOG/EORTC
40084 phase III trial currently evaluating the beneﬁt of
adding quality-controlled radiation therapy to a 6-month
course of adjuvant gemcitabine-based treatment. The
group continues to commit to the design of new strategic
trials in improving the management of pancreatic cancer
and has recently organized a consensus meeting which
aimed to delineate speciﬁc guidelines for a better
research in this dismal cancer. 27
2.4. Translational research
In addition to its clinical activities the group has
started an exhaustive program of translational research
based mainly on the PETACC2, PETACC-3 and EPOC
trials. This changed strategy towards a translational,
multidisciplinary program is regarded as the basis for the
next developments.
2.4.1. International network of pathologists and laboratories
The group has also established an international network
of pathologists and laboratories with decentralized
tissue processing. At ASCO 2005 the group presented
the use of a so-called quality-control tissue array
with which the impact of different ﬁxation times
on immunohistochemical and molecular assays can
be determined. 28 This quality-control tissue array has
been used ever since to determine the inﬂuence of
ﬁxation times on the results of immunohistochemical
analyses in the PETACC2 study. Further, researchers
evaluated the prognostic value of KRAS and BRAF in
stage II and III resected colon cancer as results of the
translational study on the PETACC-3, EORTC 40993, SAKK
60-00 trial. 29 The results of this study showed that the
KRAS mutation status does not have major prognostic
value in stage II−III CRC. However, the BRAF mutation
was prognostic for OS, particularly in patients with
microsatellite instability low (MSI-L) and stable (MSI-S)
tumors. The same markers were tested for survival after
relapse in 392 of 990 patients, who experienced disease
relapse in the PETACC-3, EORTC 40993, SAKK 60-00
studies. 30 The authors found that, although BRAF gene
status and tumor site had no prognostic value on relapse-
free survival, both, along with time to relapse (TTR), were
strong determinants of OS of patients with colon cancer
after disease relapse. Patients with BRAFmutated tumors
had a median survival of 7.5 months compared with
25.2 months for patients with BRAF wild-type tumors.
The researchers suggested these markers should be used
in stratifying patients with metastatic colon cancer for
clinical trials.
Moreover, the group will concentrate its efforts in the
next three years on the following TR projects:
2.4.2. Interaction with the EORTC virtual tumor bank
Interaction with the EORTC virtual tumor bank has been
developed so that it can function as backbone for this
collaborative research. Among the ongoing TR projects
we can mention the examination of oxaliplatin-induced
liver toxicity, the pharmacogenomic proﬁling of patients
receiving ﬂuoropyrimidine-based therapy, expression
analysis of CXCR4, Hif-1a, VEGF-C and VEGF-D, VEGFR3,
Src family kinases and in-depth examination of the
‘serrated pathway’ and its associated gene modiﬁcations
during colorectal carcinogenesis.
2.4.3. Screening platform
Due to the better knowledge of molecular pathology
not only KRAS was integrated as the ﬁrst molecular
marker in the prescription label of EGFR− antibodies
and promoted the research in further molecules in
the EGFR pathway. The better understanding and the
availability of speciﬁc inhibitors or antibodies requires
also a new trial structure, as the current routine
diagnostic does not allow indentifying the right patients
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for trials with new inhibitors. Highly targeted treatment
also means that only a small subgroup is planned to
be enrolled, increasing the efforts for the screening
procedure. As an example, to enroll 40 patients in a
phase I/II trial for BRAF mutant patients will require
to screen 500–700 patients with metastatic colorectal
cancer, a patient number similar to phase III trials
in other indications. Therefore, a common screening
platform for all patients with colorectal cancer is a
key project for the group as well as the EORTC itself,
and is currently in development in partnership with the
European Society of Pathology (ESP). The vision in this
project is that all patients at the participating centers are
ﬁrst characterized according to the molecular markers,
and then − based on this information − are enrolled in
different, parallel phase II trials. This concept has already
been applied in the BATTLE and I-SPY programs in lung
and breast cancers.
3. Conclusion
In conclusion, this review of the major achievements
of the GI Group shows that the group has played
an important role in the scientiﬁc development of
understanding and treatment of GI cancer over the last
50 years. The statements written 10 years ago in the
40th EORTC anniversary GI paper − “in the near future,
treatment of gastrointestinal tract cancer will be tailored to
the characteristics of tumours”, “our group is assessing the
possibility of doing some translational research”, “we will
now preserve resected specimens in all of the new trials” −
become reality and demonstrate the ability of the group
to foresee the future and to integrate and apply new
concepts in its scientiﬁc programs. The development of
the screening platform with the ESP in CRC described
above constitutes a major challenge and a turn in the
ways of collaboration with both individual cancer centers
and industry. If successful, this model might be extended
to other malignant tumors and set up a new era of
clinical investigations at the EORTC.
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